|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
86618 JD HEALTH-R
Nominal 
58.100 -1.200 (-2.024%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 35,290,047 | 24.506% | 58,159,881 | 53,529,941 | 46,736,150 | 30,682,267 |
| Cost of Sales | (26,398,129) | 21.965% | (44,851,304) | (41,664,605) | (36,844,642) | (23,484,985) |
| Gross Profit | 8,891,918 | 32.716% | 13,308,577 | 11,865,336 | 9,891,508 | 7,197,282 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (55,480) | -- | (315,853) | (69,859) | (98,202) | (38,352) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (39,147) | -4.066% | (85,527) | (70,757) | (96,759) | (94,165) | |
| Profit / (Loss) before Taxation | 2,863,666 | 17.395% | 4,796,676 | 2,693,348 | 695,809 | (901,491) | |
| Taxation | (272,319) | -32.755% | (639,662) | (550,468) | (312,580) | (171,327) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 5,098 | 81.812% | 4,830 | (1,039) | (3,124) | (689) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 2,596,445 | 27.453% | 4,161,844 | 2,141,841 | 380,105 | (1,073,507) | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (804,395) | -18.376% | (1,952,308) | (1,939,547) | (855,167) | (451,570) |
| Depreciation & Amortisation | 120,347 | 16.595% | 214,695 | 227,458 | 140,676 | 63,169 |
| Directors' Emoluments | -- | -- | 276,896 | 418,439 | 664,846 | 1,062,758 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 82.000 | 26.154% | 132.000 | 69.000 | 12.000 | -35.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 1.379 | 1.474 | 1.901 | 1.109 |
| NBV per share ($) | 18.116 | -- | 17.267 | 15.479 | 14.082 | 12.475 |
| Remarks: | Real time quote last updated: 22/08/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 2,596,445 |
| %Change | 27.453% |
| EPS / (LPS) | RMB 0.820 |
| NBV Per Share (¥) | RMB 18.116 |